Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
NCT ID: NCT04456972
Last Updated: 2023-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2020-06-19
2022-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After carrying out different types of high-throughput molecular analyzes on 373 endometrial carcinomas of different histological types, 4 major tumor subtypes could be identified, each with a different survival profile (the "ultra-mutated" group with POLE mutations, the "hypermuted" group with microsatellite instability (MSI), the "low number of copies" group, and the "high number of copies" group).
This histomolecular classification is not yet directly transposable to clinical practice and tumor genetic characteristics have not had any direct therapeutic impact to date.
The main objective of the study is to determine the concordance rate between molecular analysis of tumor tissue and that of cDNA in patients with endometrial cancer during treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circulating Tumor DNA Study in Patients With Endometrial Cancer
NCT05955079
Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics
NCT06083779
MSI in Circulatory DNA of Endometrial Cancer
NCT03744962
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer
NCT01119573
Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique
NCT03766672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
One arm only
One arm only
Samples of plasma to analyze ctDNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One arm only
Samples of plasma to analyze ctDNA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With recent abdomino-pelvic imaging, less than 3 months old.
* Tumor tissue sufficiently exploitable for research (\> 20% of tumor cells)
* Informed consent signed by the patient after clear and fair information about the study.
* Free patient, without tutorship, curatorship or subordination.
* Patient benefiting from a Social Security scheme or benefiting from it through a third person.
* Patient not opposed to participating in the study.
Exclusion Criteria
* Linguistic or mental refusal or incapacity to understand and / or sign the informed consent
* Patients benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection.
* Pregnant and / or lactating women
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille Mrs EVRARD, PHD
Role: PRINCIPAL_INVESTIGATOR
CHU Poitiers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Poitiers, PRC
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENDOCIRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.